Drug Target Discovery + Oligonucleotide Drug Development

Wuhan YanGeneBio is an innovative CRO technology service company specializing in drug target discovery, design, modification, and synthesis of small nucleic acid drugs (siRNA/ASO), as well as screening functional small nucleic acids in organoids, cells, and animal models. It provides customized solutions from target discovery to mechanism validation for new drug development, modernization of traditional Chinese medicine, natural product research, and the translation of small nucleic acid drug development.We integrate drug target fishing technologies such as ABPP, TPP, and Lip-MS, cross-linking mass spectrometry, Lip-MS combined with molecular docking for identifying drug-target interaction sites, SPR/MST/BLI/ITC/DSF platforms for measuring drug-target affinity, high-throughput screening platforms including protein microarrays and Olink multiplex assays, as well as core technologies such as small RNA drug design, synthesis, and organoid-based drug screening, providing clients with high-precision services for compound target identification, binding site analysis, affinity validation, and functional verification.Yanjin Biotech is committed to the mission of "Precision Drug Target Discovery and Accelerating Small Nucleic Acid Drug Transformation." With rigorous experimental design, high-quality data output, and rapid project delivery, we help global research institutions and pharmaceutical clients shorten R&D cycles and enhance drug discovery success rates.